Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients
Seminars in Arthritis and Rheumatism, Volume 35, No. 5, Year 2006
Notification
URL copied to clipboard!
Description
Objective: To describe the different types of malignancies associated with antiphospholipid antibodies (aPL). Methods: We performed a computer-assisted (MEDLINE, National Library of Medicine, Bethesda, MD) search of the literature from 1966 to 2003 to identify all cases of malignancies having aPL. Results: One hundred twenty patients were found. The mean age was 56 ± 17 years (range 5 to 88). Sixty-two (52%) patients were men and 58 (48%) were women. A heterogeneous group of malignancies were found. Regarding hematological malignancies, 10 (8%) patients suffered from B-cell lymphoma, 8 (7%) from spleen lymphoma, 7 (6%) from chronic myeloid leukemia, and 6 (5%) from non-Hodgkin's lymphoma (NHL). Regarding solid tumors, renal cell carcinoma was diagnosed in 7 (6%) patients, primary tumor with unknown origin in 7 (6%), lung adenocarcinoma in 6 (5%), breast carcinoma in 6 (5%), and melanoma in 6 (5%). The main aPL-related manifestations were thrombocytopenia (25%), cerebrovascular accidents (24%), deep vein thrombosis (19%), pulmonary embolism (15%), and heart valve lesions (9%). In 17 cases, catastrophic antiphospholipid syndrome was considered to be triggered by the malignancy. Seventy-one (63%) of 113 patients recovered or are still alive after cancer treatment. Twenty-three (35%) of 65 patients achieved aPL remission after proper treatment of the malignancy. Conclusions: It is important to bear in mind, especially in elderly patients, that thrombotic events associated with aPL can be the first manifestation of malignancy. At the same time, the presence of aPL in patients with malignancies has important implications in their treatment and prognosis. © 2006 Elsevier Inc. All rights reserved.
Authors & Co-Authors
Gómez-Puerta, José A.
Spain, Barcelona
Hospital Clinic Barcelona
Cervera, Ricard
Spain, Barcelona
Hospital Clinic Barcelona
Espinosa, Gerard
Spain, Barcelona
Hospital Clinic Barcelona
Aguiló, Sira
Spain, Barcelona
Hospital Clinic Barcelona
Bucciarelli, Silvia
Spain, Barcelona
Hospital Clinic Barcelona
Ramos-Casals, Manuel
Spain, Barcelona
Hospital Clinic Barcelona
Ingelmo, Miguel
Spain, Barcelona
Hospital Clinic Barcelona
Asherson, Ronald A.
South Africa, Cape Town
Faculty of Health Sciences
Font, Josep Maria
Spain, Barcelona
Hospital Clinic Barcelona
Statistics
Citations: 129
Authors: 9
Affiliations: 2
Identifiers
Doi:
10.1016/j.semarthrit.2005.07.003
ISSN:
00490172
Research Areas
Cancer
Health System And Policy
Participants Gender
Male
Female